Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Hutchison MediPharma Raises $12.5 Million from Mitsui

publication date: Nov 8, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Hutchison MediPharma, a subsidiary of Chi-Med, announced a $12.5 million investment from Mitsui & Co., which received convertible Preference Shares that convert into 12.2% of Hutchison MediPharma. The transaction implies a $100 million valuation for the company, which is the drug discovery arm of Chi-Med. MediPharma said the money would support its various drug development programs. More details....

Stock Symbol: (AIM: HCM)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners